MED-EL Study Shows That a Quarter of Adults Have Never Had The... - 01 March 2019 03:17

LONDON, March 1, 2019, /PRNewswire-AsiaNet/-- BRITS are the worst in the world for having their hearing tested, a major study reveals. Almost half (46%) have NEVER had their ears checked, compared to just 11% in Russia and 19% in the US. In an international study of 11,000 adults ...

  Trianni, Inc. Announces Issuance of Patent in Japan - 01 March 2019 00:00

SAN FRANCISCO, Feb. 28, 2019 /PRNewswire-AsiaNet/ -- Trianni, Inc. ("TRIANNI") announced today that the Japan Patent Office granted the patent for TRIANNI's leading technology, The Trianni Mouse(TM). The Trianni Mouse is a transgenic mouse R&D platform for the discovery of fully-human monoclonal ant...

  Zsquare Secures $10m for Its Groundbreaking 0.45mm Fiber, High... - 27 February 2019 11:01

TEL AVIV, Israel, February 27, 2019 /PRNewswireAsiaNet/ -- Company's line of miniature endoscopes set to meet a broad range of unserved clinical indications Zsquare, developer of the MultiPly(TM) single-use endoscopic platform, has secured $10M in financing for further development of its ...

  Gracell Biotechnologies Completes $85 Million Series B for Imm... - 26 February 2019 11:07

SUZHOU and SHANGHAI, China, Feb. 26, 2019/PRNewswire-AsiaNet/-- -- Gracell addresses the issues of complex manufacture and high cost of cellular gene therapeutics Gracell Biotechnologies, Co., Ltd. ("Gracell") announced the completion of its $85 million series B funding today. The financing was led by Tema...

  Texas Cardiac Arrhythmia Institute at St. David's Medical Cent... - 25 February 2019 10:08

AUSTIN, Texas, Feb. 25, 2019 /PRNewswire-AsiaNet/ -- The Texas Cardiac Arrhythmia Institute at St. David's Medical Center recently began enrolling patients to participate in the DIAMOND-AF II clinical trial to examine the effectiveness of the DiamondTemp System in treating patients with persistent a...

  PharmaEssentia and AOP Orphan Receive EU Approval of Besremi(T... - 22 February 2019 09:54

BURLINGTON, Mass., Feb. 22, 2019 /PRNewswire-AsiaNet/-- PharmaEssentia today announced that the European Commission (EC) has approved Besremi(R) (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. The European market author...

  Mallinckrodt Announces Interim Analysis Results for Therakos(R... - 21 February 2019 19:00

STAINES-UPON-THAMES, United Kingdom, Feb. 21, 2019 /PRNewswire-AsiaNet/ -- -- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today a...

  Takeda, Microsoft and EURORDIS release report with action plan... - 20 February 2019 21:00

NEW YORK and BRUSSELS, Feb. 20, 2019 /PRNewswire-AsiaNet/ -- - Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health sy...

  Merck Receives First U.S. Patent for Improved CRISPR Genome-Ed... - 20 February 2019 00:00

DARMSTADT, Germany, Feb. 20, 2019 /PRNewswire-AsiaNet/-- -- Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research -- Helps modify difficult-to-access regions of the genome, increasing genome coverage Merck ( https://c212.net/c/link/...

  Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(... - 17 February 2019 10:08

DARMSTADT, Germany and NEW YORK, Feb. 17, 2019 /PRNewswire-AsiaNet/ -- Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAV...